JMPer Cable

Latest Posts

• Mauro Gerber of HUBER+SUHNER on why ‘smart factory’ and ‘digitization’ mean little without the democratization of statistical thinking

  An analytics advocate interview

  Meg_Hermes

  JMPer Cable |

  Dec 19, 2023 1:46 PM

  1343 views | 0 replies
  

• Jonathan Williams, PhD, on standardizing best practices, developing an analytics champion within senior leadership and how wide-ranging JMP capabilities have accelerated IQE’s analytics transformation

  An analytics advocate interview

  Meg_Hermes

  JMPer Cable |

  Dec 19, 2023 1:46 PM

  1790 views | 0 replies
  

• Dan Fortune of Hexion on the symbiosis of chemistry and statistics, transitioning from Excel and finding inspiration at Discovery Summit

  An analytics advocate interview

  Meg_Hermes

  JMPer Cable |

  Dec 19, 2023 1:46 PM

  1354 views | 0 replies
  

• Tom Bidwell of INEOS Composites on culture change and how the chemical industry is increasingly embracing statistics

  An analytics advocate interview

  Meg_Hermes

  JMPer Cable |

  Dec 19, 2023 1:46 PM

  1010 views | 0 replies
  

• How to perform gene expression data analysis in JMP® Pro 17: Part 1 - Introduction

  The new version of JMP Pro encompasses nearly all functionality formerly available in JMP Genomics.    

  Valerie_Nedbal

  JMPer Cable |

  Dec 19, 2023 1:46 PM

  2237 views | 1 replies
  

• Hover labels: Understanding the extensions framework

  Get a better look at the underlying "plumbing" layer that powers the porcelain layer. 

  LisaG

  JMPer Cable |

  Dec 19, 2023 1:43 PM

  3543 views | 1 replies
  

• New features for Distribution in JMP 16

  The Distribution platform can be used to explore the distribution of a single variable. This is a rich platform that allows many different visuals, statistics, and tests on variables. This blog post details the new features to the Distribution platform in version 16 of JMP.

  tonya_mauldin

  JMPer Cable |

  Dec 19, 2023 1:43 PM

  3984 views | 0 replies
  

• Scatterplot Matrix Christmas tree

  Is there anything more magical than a beautifully decorated Christmas tree?

  sabrinafong8

  JMPer Cable |

  Dec 19, 2023 1:43 PM

  2472 views | 0 replies
  

• Using the ! (NOT) operator and how to make it useful in your JSL code

  Learn what the ! (NOT) operator is and see examples of how you can make use of it in your JSL code.

  nickholmes13

  JMPer Cable |

  Dec 19, 2023 1:41 PM

  5049 views | 0 replies
  

• VSCode and JSL: a different scripting environment

  Do you do any of the following Script JSL as well as other languagesUse git or other version control software for you JSL scriptsAlready use VSCode for other thingsJust want to code JSL in something that feels more like an IDE Then I've got some good news! YAY!  

  vince_faller

  JMPer Cable |

  Dec 19, 2023 1:41 PM

  5502 views | 4 replies
  

• Add() vs. + vs. Sum(): What’s the difference?

  Ever been confused when trying to add numeric values and ended up with a missing value as the result? Maybe you discovered the Sum() function to get around the problem but never really understood why it worked. In this blog post, I explain the Add() function, plus (+) operator, and the Sum() function to help you get the results you need from your script or column formula.  

  Wendy_Murphrey

  JMPer Cable |

  Dec 19, 2023 1:41 PM

  6052 views | 2 replies
  

• JMP developers tell all this fall – and answer your questions, too

  The first Mastering JMP Developer Tutorial is Oct. 21. Ryan Lekivetz talks about using covariates when designing experiments. Ryan makes learning about designing experiments fun, and recently did a small experiment with his masked but recognizable co-workers in North Carolina.   

  gail_massari

  JMPer Cable |

  Dec 19, 2023 1:39 PM

  2585 views | 1 replies
  

• Developer Tutorial: From sports to stats to generalized regression in JMP Pro

  Starting Nov. 4, Developer Clay Barker will present three Developer Tutorials.

  gail_massari

  JMPer Cable |

  Dec 19, 2023 1:39 PM

  2489 views | 1 replies
  

• Self-described “analytics evangelist” Craig DePorter of Omya discusses why analytics enablement means learning more with less

  Advocating for analytics at Omya Craig DePorter of Omya

  Meg_Hermes

  JMPer Cable |

  Dec 19, 2023 1:38 PM

  3335 views | 0 replies
  

• Safety Results IIIb: Significant Adverse Events by AE Risk Report in JMP® Clinical

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety can be evaluated. My previous blogs demonstrated how to capture SAEs using Adverse Events Narrative³, and Discontinuations Due⁴ to AEs and TEAE⁵ with Adverse Events Distribution. There is a final step...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 16, 2023 8:00 AM

  1079 views | 0 replies
  

• Safety Results IIIa: TEAE by Adverse Events Distribution in JMP® Clinical

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety can be evaluated. My previous blogs demonstrated how to evaluate SAEs by Adverse Events Narrative³ and Discontinuations Due to AEs⁴ by Adverse Events Distribution. We'll now look at the third step for...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 14, 2023 8:00 AM

  3934 views | 0 replies
  

• Safety Results II: Discontinuations due to AEs evaluated by AE Distribution in JMP® Clinical

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety can be evaluated. My blog, Safety Result I, explained how to use the Adverse Events Narrative to summarize the individual information³ for those subjects that had a SAE in CR for Latuda⁴. The below fi...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 9, 2023 9:00 AM

  672 views | 0 replies
  

• Safety Results I: Using the Adverse Events Narrative in JMP® Clinical to describe deaths and SAEs

  In our recent paper, CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2, we followed FDA NDA (New Drug Application) or CR (Clinical Reviews) templates to show how drug safety is evaluated by reviewers at the U.S. FDA. The typical template, shown below, is from an NDA for Mydayis³. The major content in the safety review can be found in the Safety Results section. Assessin...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 7, 2023 1:30 PM

  1338 views | 0 replies
  

• Summary of clinical trials using JMP® Clinical

  Before we can understand clinical trial data in detail, we need to understand the protocol or trial design to get a big picture of the clinical trial data. This data can be described in three ways: trial, event, and treatment emergent adverse events (TEAE) summaries, as explained in our recent paper CDISC Enables Efficient Streamlining of Clinical Trial Safety Evaluation^1,2.
  
  Trial summaries can be...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 7, 2023 1:30 PM

  1053 views | 0 replies
  

• New Medical Queries: FMQ and AFMQ Implemented in JMP® Clinical

  The FDA announced the release of the FDA Medical Query (FMQ) and Algorithmic FDA Medical Queries (AFMQ) at the Duke Margolis-FDA Workshop: Advancing Premarket Safety Analytics¹ on Sept 14, 2022. The description of FMQ and AFMQ can be found in this FDA presentation: Advancing Premarket Safety Analytics². Traditional medical queries (Standard Medical Queries (SMQ))³ focused primarily on MedDRA prefe...

  Wenjun_Bao_JMP

  JMPer Cable |

  Nov 7, 2023 1:29 PM

  3885 views | 0 replies